Sitaxsentan in the management of pulmonary arterial hypertension

American Journal of Health-System Pharmacy

Volumn 64, Issue 4, 2007, Pages 363-368

  Benedict, Neal J ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Binding; Dosage; Drug administration; Drug interactions; Hypertension; Hypotensive agents; Mechanism of action; Pharmacokinetics; Sitaxsentan; Toxicity

Indexed keywords

AMINOTRANSFERASE; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; LIVER ENZYME; MITOGENIC AGENT; PLACEBO; SITAXSENTAN;

ACUTE HEPATITIS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; CARDIOPULMONARY HEMODYNAMICS; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOTENSION; LIVER FUNCTION TEST; LUNG EDEMA; LUNG PARENCHYMA; NAUSEA; PERIPHERAL EDEMA; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RANDOMIZATION; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 33847106052     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060357     Document Type: Review

References (23)

1. Rich W, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107:216-23.
2. Fung SM, Ferrill MJ. Treatment of pulmonary arterial hypertension with sildenafil. Hosp Pharm. 2004; 39:243-53.
3. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991; 115:343-9.
4. Badesch D, Abman S, Ahearn G et al. Medical therapy for pulmonary arterial hypertension. Chest. 2004; 126:35S-62S.
5. Tracleer (bosentan) manufacturer information. South San Francisco, CA: Actelion Pharmaceuticals; 2002.
6. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001; 358:1119-23.
7. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346:896-903.
8. Hoeper MM, Galie N, Simonneau G et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165:1209-16.
9. Newman J, Fanburg B, Archer S et al. Pulmonary arterial hypertension: future directions report of a National Heart Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004; 109:2947-52.
10. Weber C, Schmitt R, Birnboeck H et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996; 60:124-37.
11. Givertz MM, Colucci WS, LeJemtel TH et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000; 101:2922-7.
12. Wu C, Chan MF, Stavros F et al. Discovery of TBC11251, a potent long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997; 40:1690-7.
13. A receptor antagonist. Pulm Pharmacol Ther. 2000; 13:87-97.
14. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001; 41:851-76.
15. Wu C, Decker E, Blok N et al. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5- ylsulfamoyl)-thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally available endothelin antagonist. J Med Chem. 2004; 47:1969-86.
16. Barst R, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care Med. 2004; 169:441-7.
17. Givertz MM, Colucci WS, LeJemtel TH et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000; 101:2922-7.
18. Barst RJ, Rich S, Widlitz A et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest. 2002; 121:1860-8.
19. O'Callaghan DS, Gaine SP. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Int J Clin Pract. 2006; 60:475-81.
20. A receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol. 2004; 44:S80-4.
21. Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective entothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47:2049-56.
22. Langleben D, Hirsch A, Shalit E et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2004; 126:1377-81.
23. Coyne T, Dixon R. Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxsentan. Chest. 2005; 128:366S. Abstract.